How does Cassia abbreviata work as a laxative?

Cassia abbreviata acts primarily through anthraquinone glycosides, specifically sennosides, found in its bark. These compounds resist digestion in the small intestine but are metabolized by colonic bacteria into active metabolites like rhein anthrone. These metabolites stimulate peristalsis in the colon and inhibit water and electrolyte absorption, effectively softening stools and promoting evacuation. This mechanism is consistent with other stimulant laxatives (Evidence Level: B).

Can I take Cassia abbreviata if I am on heart medication?

You should avoid Cassia abbreviata if you take heart medications, particularly cardiac glycosides like digoxin. The herb's strong laxative effect can cause significant potassium loss (hypokalemia), which increases the risk of digitalis toxicity and arrhythmias. Additionally, the potential for electrolyte imbalance may interfere with antiarrhythmic drugs or diuretics. Consult a healthcare provider before use (Evidence Level: C/Theoretical).

What is the safe dosage for Cassia abbreviata bark?

There is no established standardized clinical dosage for Cassia abbreviata due to limited human trials. Traditional preparation involves a decoction made from a small amount of dried bark. Because the plant possesses potent purgative activity, users must exercise extreme caution to avoid severe diarrhea. It is recommended to start with the lowest possible traditional amount and avoid long-term use (Evidence Level: Traditional).

Is Cassia abbreviata safe during pregnancy?

No, Cassia abbreviata is contraindicated during pregnancy. The anthraquinone content stimulates uterine contractions and smooth muscle activity, which poses a significant risk of miscarriage or premature labor. Furthermore, the severe electrolyte disturbances and dehydration caused by its purgative effects are dangerous for both the pregnant person and the fetus. It should be strictly avoided (Evidence Level: C).

What are the side effects of taking Cassia abbreviata?

The most common side effects include severe abdominal cramping and watery diarrhea due to the herb's strong stimulant laxative properties. Users may also experience nausea and dehydration. Prolonged use can lead to electrolyte imbalances, specifically hypokalemia (low potassium), and potential kidney irritation. Due to these risks, usage should be short-term and monitored closely (Evidence Level: C).

Cassia Abbreviata (Cassia abbreviata)

Fiche d'information compilée à partir de PubMed

Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.

Compilé à partir de 30 articles PubMed · modèle : gemma4:31b

Résumé

Cassia abbreviata is a deciduous tree native to the tropics, particularly Africa, used in traditional medicine for various ailments [PMID:29126990]. Research indicates potential anti-diabetic, anti-HIV-1, and antimalarial activities [PMID:28392962, 33922460, 9039271].

Contexte

Cassia abbreviata is a small to medium-sized branched umbrella-shaped deciduous tree widely spread in the tropics, especially Africa [PMID:29126990].

Usages traditionnels

It has a long history in traditional medicine for treating headaches, diarrhea, constipation, skin diseases, malaria, syphilis, pneumonia, stomach troubles, uterine pains, and gonorrhea [PMID:29126990]. It is also used in Sub-Saharan Africa for treating HIV-1 infection [PMID:34068829] and sexually transmitted diseases in Zimbabwe [PMID:11483371]. In Tanzania, it is traditionally used for respiratory bacterial infections [PMID:35406911].

Composés actifs

Isolated compounds include cassiabrevone, guibourtinidol-(4α→8)-epiafzelechin, taxifolin, oleanolic acid, piceatannol, and palmitic acid [PMID:33922460, 34068829]. Other identified constituents include benzophenone glucosides, B-type proanthocyanidin dimers [PMID:34965114], and 2,4-trans-7,4'-dihydroxy-4-methoxyflavan [PMID:11711106]. Seed oil contains oleic acid (37.8%), palmitic acid (26.5%), and linoleic acid (26.7%) [PMID:26004707].

Mécanisme d'action

In skeletal muscle cells, aqueous extracts enhance glucose uptake and GLUT-4 translocation [PMID:33788626]. Certain compounds (oleanolic acid, palmitic acid, taxifolin, piceatannol, guibourtinidol-(4α→8)-epiafzelechin, and cassiabrevone) block HIV-1 entry into cells [PMID:34068829]. Stem bark extracts may lower blood pressure via a histamine-related substance acting on H1 receptors [PMID:1308839].

Preuves cliniques

Preuve DType 2 Diabetes (Animal Model)

Ethanol extract of stem bark exhibited hypoglycemic effects in diabetic albino rats [PMID:28392962].

Preuve DHIV-1 Infection (In Vitro)

Six bioactive compounds inhibit HIV-1 infection by blocking viral entry into cells [PMID:34068829, 33922460].

Preuve DMalaria (In Vitro/Animal Model)

Organic fractions showed high in vitro activity against Plasmodium falciparum [PMID:9039271] and demonstrated antimalarial activity in mice with an ID50 of 111.0 mg/kg [PMID:20209008].

Preuve DHepatotoxicity (Animal Model)

Root extract exhibited hepatoprotective activities in D-galactosamine-induced hepatotoxicity in rats [PMID:29126990].

Sécurité et effets indésirables

In chickens, high doses (500 mg/kg) of stem bark extract caused hepatotoxicity and depressed growth performance [PMID:31250251]. In brine shrimp toxicity tests, extracts exhibited high toxicity with an LC50 of 12.7 microg/ml [PMID:20162095]. The LD50 in rats/mice via IP injection was reported as 500-750 mg/kg [PMID:1308715].

Grossesse et allaitement

Administration to pregnant mice and rats did not cause expulsion or resorption of fetuses at doses that were not toxic to the animals [PMID:1308715].

Interactions médicamenteuses

Extracts inhibited CYP1A2, CYP2C9, and CYP2C19 enzyme activities (Ki of 4.86, 5.98, and 1.58 µg/mL respectively) and are potential time-dependent inhibitors (TDI) for CYP1A2 and CYP2C19 [PMID:27399660].

Synthèse des preuves

The evidence is primarily based on in vitro studies and animal models (Level D), demonstrating significant pharmacological potential for anti-diabetic, anti-viral, and antimalarial applications, though human clinical trials are lacking.

Sources PubMed

1.PMID: 28392962 (2017) — Anti-Diabetic Effects of an Ethanol Extract of Cassia Abbreviata Stem Bark on Diabetic Rats and Possible Mechanism of Its Action: - Anti-diabetic Properties of Cassia abbreviata. · Journal of pharmacopuncture
2.PMID: 33922460 (2021) — Chemical Constituents of Cassia abbreviata and Their Anti-HIV-1 Activity. · Molecules (Basel, Switzerland)
3.PMID: 33788626 (2021) — Cassia Abbreviata Enhances Glucose Uptake and Glucose Transporter 4 Translocation in C2C12 Mouse Skeletal Muscle Cells. · Journal of evidence-based integrative medicine
4.PMID: 31250251 (2019) — Effects of Cassia abbreviata extract and stocking density on growth performance, oxidative stress and liver function of indigenous chickens. · Tropical animal health and production
5.PMID: 34068829

Cassia Abbreviata

Sources et citations